Tal Medical is developing a novel, proprietary Low Field Magnetic Stimulation (LFMS) technology discovered at McLean Hospital, a Harvard University teaching hospital.
LFMS utilizes a unique magnetic field waveform, with a mechanism of action different than existing treatment including other brain stimulation techniques, such as electroconvulsive therapy (ECT) or transcranial magnetic stimulation (TMS). In particular, LFMS acts to modulate, but does not directly drive brain and muscle tissue. LFMS also uses a different waveform (shape, frequency, etc.) and spatial distribution than these other therapies.
LFMS’ direct physiological effects have been highlighted by a sham-controlled neuroimaging study with LFMS that demonstrated an immediate decrease in brain glucose utilization, the opposite of the effect reported in published studies with rTMS and ECT.
The Tal Medical LFMS Device is limited by US Federal Law to Investigational Use.